|
Match
|
Document |
Document Title |
|
|
7384774 |
Helper-free rescue of recombinant negative strand RNA virus
The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present...
|
|
|
7374751 |
QS-21 and IL-12 as an adjuvant combination
Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition...
|
|
|
7354706 |
Use of photopolymerization for amplification and detection of a molecular recognition event
The invention provides methods to detect molecular recognition events. The invention also provides methods to detect the presence of or identify a target species based on its interaction with one...
|
|
|
7344722 |
Cold-adapted influenza virus
The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were...
|
|
|
7341988 |
Method of treating influenza with geranyl-geranyl acetone
To provide a novel preventive and/or therapeutic agent against a virus, disclosed is a preventive and/or therapeutic agent against a viral infection containing geranyl-geranyl acetone as an active...
|
|
|
7339037 |
Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an...
|
|
|
7323183 |
Vaccine compositions including chitosan for intranasal administration and use thereof
There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.
|
|
|
7316813 |
Influenza vaccine composition
An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin...
|
|
|
7314626 |
Use of peptide vectors to improve the immune response to antigens
The invention relates to conjugates of an antigen coupled to a linear derivative of a β-stranded antibiotic peptide, which are useful for immunogenic agents to enhance a CTL response. Two groups...
|
|
|
7285289 |
Nanoparticle vaccines
The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed...
|
|
|
7255859 |
Monoclonal antibodies against the epitope YPYDVPDYA, a process for their production and their use
The invention concerns monoclonal antibodies against the epitope YPYDVPDYA (SEQ ID NO: 1) which is derived from the haemagglutinin of the human influenza virus and are suitable for the detection...
|
|
|
7169395 |
Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
Immunogenic compositions for administration to adults, particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and by influenza virus...
|
|
|
7169394 |
Mycoplasma hyopneumoniae bacterin vaccine
The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition...
|
|
|
7157089 |
Immune responses using compositions containing stress proteins
The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a...
|
|
|
7128909 |
Immunstimulating lipid formulation
A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monoglyceride preparations having at least 80% monoglyceride...
|
|
|
7090853 |
Noscapine derivatives as adjuvant compositions and methods of use thereof
An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines.
|
|
|
7070781 |
Nontoxic mucosal adjuvant
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic...
|
|
|
7052701 |
Inactivated influenza virus vaccine for nasal or oral application
The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said...
|
|
|
7037707 |
Method for generating influenza viruses and vaccines
The present invention is based on the discovery that a high titer reassortant influenza virus is produced in mammalian cell culture by replacing the NS gene of the A/PuertoRico/3/24 master strain...
|
|
|
7018638 |
Mycoplasma hyopneumoniae bacterin vaccine
The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition...
|
|
|
6974686 |
Recombinant tryptophan mutants of influenza
Recombinant PB2 tryptophan variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such...
|
|
|
6951649 |
Methods of making neuraminidase-supplemented compositions
The present invention relates to a method for formulating a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement of the vaccine composition is that the vaccine...
|
|
|
6890710 |
Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that...
|
|
|
6872395 |
Viruses comprising mutant ion channel protein
A method to prepare viruses lacking ion channel activity is provided.
|
|
|
6843996 |
Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation
Recombinant PB2 variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and...
|
|
|
6838080 |
Induction of immunoglobulin class switching by inactivated viral vaccine
The present disclosure provides methods and compositions for inducing an immune response to an antigen, especially in an immunogenic composition comprising sialic acid where the antigen comprises...
|
|
|
6824793 |
Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the...
|
|
|
6797276 |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a ystemic or mucosol antibody...
|
|
|
6669943 |
Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated...
|
|
|
6649172 |
Amphipathic aldehydes and their uses as adjuvants and immunoeffectors
This invention relates to novel aldehyde containing compounds and their uses as adjuvants and immunoeffectors.
|
|
|
6641816 |
Use of poxviruses as enhancer of specific immunity
The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus...
|
|
|
6632431 |
Anti-idiotypic antibody against FimH adhesion of uropathogenic type I-fimbriated Escherichia coli, compositions containing same and method for using same
The present invention relates to an anti-idiotypic antibody or antigen-binding fragment against FimH adhesin of uropathogenic Type I-fimbriated Escherichia coli and an immunizing composition...
|
|
|
6565849 |
Methods of enhancing activity of vaccines and vaccine compositions
Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects...
|
|
|
6534065 |
Influenza vaccine composition with chitosan adjuvant
A vaccine composition adapted for mucosal administration is provided. The composition includes one or more influenza vaccine antigens and an effective adjuvant amount of an acid addition salt of a...
|
|
|
6531313 |
Invasive bacterial vectors for expressing alphavirus replicons
The present invention is directed to a bacterial delivery system for delivering alphavirus replicon DNA into an animal or animal cells with the replicon encoding one or more heterologous genes to...
|
|
|
6528064 |
Recombinant trytophan mutants of influenza
Recombinant PB2 tryptophan variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such...
|
|
|
6524588 |
Attenuated vaccination and gene-transfer virus, a method to make the virus and a pharmaceutical composition comprising the virus
RNA polymerase I transcription in vivo in transiently DNA-transfected cells has been used for expression of influenza vRNA molecules coding for chloramphenicol acetyltransferase (CAT) in anti-sense...
|
|
|
6485729 |
Neuraminidase-supplemented compositions
An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available...
|
|
|
6355777 |
P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
Canine monocytic ehrlichiosis, caused by Ehrilichia canis is a potentially fatal disease of dogs that requires rapid and accurate diagnosis in order to initiate appropriate therapy leading to a...
|
|
|
6344354 |
Influenza virus replicated in mammalian cell culture and vaccine production
The invention provides replication of high growth influenza virus strains, derived from clinical isolates, in cultured mammalian cells by infecting the mammalian cells with the high growth strains...
|
|
|
6337181 |
Method of specifying vaccine components for viral quasispecies
An algorithm for determining the viral antigenic protein variants to be used to construct vaccines designed to immunize against variable viral populations (quasispecies) is described. The method...
|
|
|
6337070 |
Polypeptides for use in generating anti-human influenza virus antibodies
The invention provides an anti-human influenza virus antibody which recognizes the stem regions of haemagglutinin molecules of the H1N1 and H2N2 subtypes and has a neutralization activity but does...
|
|
|
6316243 |
Genetically engineered attenuated double-stranded RNA viruses
The present invention relates to engineering attenuated viruses by altering a non-coding region or the coding sequence of a viral gene. Alterations of the non-coding regions which regulate...
|
|
|
6231860 |
Stabilizers for live vaccines
Stabilizers for live vaccines and attenuated mono- or multivalent live vaccines, stabilized vaccines containig such stabilizers, and methods for preparing such vaccines, are disclosed. Said...
|
|
|
6221362 |
Avian polynucleotide formula
The avian vaccine formula comprises at least three polynucleotide vaccine valencies each comprising a plasmid integrating, so as to express it in vivo in the host cells, a gene with one avian...
|
|
|
6136606 |
Influenza vaccine compositions
The invention provides a vaccine composition in the form of a kit, comprising a first container containing an antigenic preparation comprising influenza antigen or antigens; and a second container...
|
|
|
6136319 |
Method of treating viral diseases in animals
A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a...
|
|
|
6090609 |
Crystallized N-terminal domain of influenza virus matrix protein M1 and method of determining and using same
The matrix protein, M1, of influenza virus strain A/PR/8/34 has been purified from virions and crystallized. The crystals consist of a stable fragment (18 Kd) of the M1 protein. X-ray diffraction...
|
|
|
6090406 |
Potentiation of immune responses with liposomal adjuvants
A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal,...
|
|
|
6024963 |
Potentiation of immunogenic response
An enhanced immune response to antigens, particularly normally weakly-immunogenic viral antigens, such as the HA antigen from influenza virus, is achieved by coadministering the antigen in two...
|